Back to top
more

Evolent Health (EVH)

(Delayed Data from NYSE)

$13.36 USD

13.36
20,265,867

-11.21 (-45.62%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $13.47 +0.11 (0.82%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Internet - Software

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Evolent Health (EVH) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of -86.67% and 0.67%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.

Why Evolent Health (EVH) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

KANZHUN LIMITED Sponsored ADR (BZ) to Report Q3 Results: What Awaits?

by Zacks Equity Research

Kanzhun (BZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolent Health (EVH) Reports Next Week: What to Know Ahead of the Release

by Zacks Equity Research

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 42.86% and 2.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Moves 12.8% Higher: Will This Strength Last?

by Zacks Equity Research

Evolent Health (EVH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 61.90% and 6.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

New Strong Buy Stocks for January 5th

by Zacks Equity Research

ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.

How Much Upside is Left in Evolent Health (EVH)? Wall Street Analysts Think 59.66%

by Zacks Equity Research

The consensus price target hints at a 59.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Best Momentum Stocks to Buy for November 20th

by Zacks Equity Research

EVH, ACGL and AREC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 20, 2023.

Wall Street Analysts See a 56.84% Upside in Evolent Health (EVH): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 56.8% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Evolent Health (EVH) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 233.33% and 0.55%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Celestica (CLS) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Celestica (CLS) delivered earnings and revenue surprises of 6.56% and 2.42%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Evolent Health (EVH) Could Surge 76.14%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Evolent Health (EVH) points to a 76.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

CrowdStrike (CRWD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

CrowdStrike (CRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Believe Evolent Health (EVH) Could Rally 77.45%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 77.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Evolent Health (EVH) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Evolent Health (EVH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 55.56% and 1.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Beats Q1 Earnings Estimates

by Zacks Equity Research

Evolent Health (EVH) delivered earnings and revenue surprises of 40% and 1.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?